Citations

Clear

360 citation(s) found for "Simmons, D".

TDP-43–Associated Neurodegenerative Disease Conceptualization and Integrated Staging
Benatar, Michael, Lagier‐Tourenne, Clotilde , Gregory, Jenna, Al-Chalabi, Ammar, Boeve, Bradley F., Maragakis, Nicholas J., Wuu, Joanne, Zeier, Zane, Onyike, Chiadi, Lewcock, Joe, Hovinga, Collin, Jafar-nejad, Paymaan, Uspenskaya, Olga, Simmons, Adam, Browne, Susan E., Rohrer, Jonathan, Petrucelli, Leonard, Shapiro, Jacquelyn, Scharper, Deb, Boxer, Adam, Staffaroni, Adam M. , Dacks, Penny, Dave, Kuldip D. , Majo, Martina de, Mitic, Laura, Fradette, Stephanie , Haeberlein, Samantha Budd , Simuni, Tanya, Dunn, Billy, Lee, Edward B., Js, Gregory , Benatar, Michael, Barmada, Sami, Jicha, Gregory A. , Al‐Chalabi, Ammar , Boeve, Bradley F. , Jack, Clifford R. , Seeley, William W. , Maragakis, Nicholas J. , Wuu, Joanne , Zeier, Zane R. , Hovinga, Collin A. , Jafar‐Nejad, Paymaan , Uspenskaya, Olga, Simmons, Adam, Browne, Susan E. , Petrucelli, L, Ostrow, Lyle W. , Dacks, Penny A. , Turner, Martin R. , Majo, Martina de , Simuni, Tanya , McMillan, Corey T. , Lee, Edward B.

Mayo Clinic

JAMA Neurology | August 24, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1001/jamaneurol.2026.2812 | PMID 42636000 Get It

Importance Classifying disease based on underlying pathobiology rather than clinical phenotype has implications for the development of biomarkers and therapy development. Observations Transactive response DNA-binding protein 43 kDa (TDP-43) pathology is observed across a range of clinically defined neurodegenerative disorders including limbic predominant age-related encephalopathy (LATE), most cases of amyotrophic lateral sclerosis (ALS), inclusion body myositis, multisystem proteinopathy, and approximately half the cases of frontotemporal dementia (FTD). Despite this shared biology, the current nosology for these neurodegenerative disorders is based on their distinct clinical phenotypes. An alternative approach recognizes the central role of TDP-43 pathology in disease pathogenesis, reserving the use of clinical terms like ALS, FTD, or LATE to describe phenotypic manifestations of underlying pathobiology. This approach also recognizes the converging biomarker and neuropathological data indicating that pathology begins presymptomatically, before the overt clinical manifestations of disease appear. Conclusions and Relevance In proposing a pathobiological definition of disease, the goal is to provide a road map for developing biomarkers that accurately reflect the underlying pathobiology of disease and for advancing therapeutic candidates that effectively target fundamental disease mechanisms.
Pathologic Complete Response (pCR) Rate and Predictors of Response to Taxane, Trastuzumab, and Pertuzumab in HER2‑Positive Breast Cancer: Secondary Analyses of EA1181/CompassHER2 pCR
Tung, Nadine , DeMichele, Angela , Winer, Eric P. , Wright, Jean L. , Recht, Abram , Weiss, Anna C., Tjoe, Judy A., Feldman, Sheldon M. , Smith, Mary Lou , O’Sullivan, Ciara C. , Sardesai, Sagar D., Irvin, W. J., Battelli, Chiara, Krie, Amy, D’Abreo, Nina , Shah, Payal D. , DeMichele, Angela , Prat, Aleix , Winer, Eric , Wright, Jean L , Recht, Abram , Rocque, Gabrielle , O'Sullivan, Ciara Catherine , Tang, Shou-Ching , Modi, Shanu , Bagegni, Nusayba , Krie, Amy K , Telli, Melinda L , Borges, Virginia F , D'Abreo, Nina , Shah, Payal D , Villagrasa, Patricia , Badve, Sunil S , Partridge, Ann H , Miller, Kathy D , Carey, Lisa A , Wolff, Antonio C , Tung, Nadine , Zhao, Fengmin , Weiss, Anna , Tjoe, Judy A., Rocque, Gabrielle B. , Sardesai, Sagar , Modi, Shanu , Irvin, William , Unni, Nisha G , George, Mridula Annette , Telli, Melinda L. , Borges, Virginia F. , Badve, Sunil , Partridge, Ann H. , Miller, Kathy D. , Carey, Lisa A. , Wolff, Antonio C.

Mayo Clinic

Journal of Clinical Oncology | August 20, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1200/jco-25-02255 | PMID 42623567 Get It

PURPOSE EA1181 (ClinicalTrials.gov identifier: NCT04266249 ) is a single-arm trial evaluating neoadjuvant taxane, trastuzumab, and pertuzumab (THP) in patients with clinical stage II/IIIa human epidermal growth factor receptor 2 (HER2)–positive breast cancer. This report focuses on the secondary end points of pathologic complete response (pCR) rates and associated factors. The primary end point—3-year recurrence-free survival among patients achieving a pCR (ypT0/Tis, ypN0)—will be reported when data mature. METHODS Patients received four cycles of trastuzumab and pertuzumab (HP) with either once per week paclitaxel (12 weeks) or docetaxel (every 3 weeks for four cycles), followed by surgery. Clinicopathologic characteristics were assessed in all patients. The HER2DX pCR score was determined using diagnostic biopsy samples in a representative subset. Logistic regression models identified factors associated with pCR. RESULTS A total of 2,175 patients were enrolled (781 HER2+/estrogen receptor‑negative [ER–]; 1,394 HER2+/ER+). Of 2,141 patients who initiated THP, the overall pCR rate was 43.8%: 63.7% in HER2+/ER– and 32.4% in HER2+/ER+ tumors. Higher pCR rates were observed in tumors that were ER-negative or low ER expressing, progesterone receptor-negative or low expressing, HER2 immunohistochemistry (IHC) 3+, and in patients treated with once per week paclitaxel. T3 disease was associated with a lower pCR rate in HER2+/ER– tumors; otherwise, tumor (T) and nodal (N) stage did not significantly affect pCR. Among 569 patients assessed for HER2DX pCR scores, a high score was independently associated with higher pCR rates, after adjustment for clinicopathologic variables. CONCLUSION Neoadjuvant THP achieved pCR in nearly two-thirds of patients with HER2+/ER– and one third with HER2+/ER+ breast cancer. Low hormone receptor expression, HER2 IHC 3+ status, once per week paclitaxel use, and a high HER2DX pCR score were independent predictors of pCR. These findings should help optimize risk stratification and treatment personalization for patients with HER2-positive breast cancer.
Phase II Randomized Trial of Radium-223 Dichloride and Cabozantinib in Patients With Renal Cell Carcinoma With Bone Metastases: RADICAL (Alliance A031801)
McKay, Rana R. , Ballman, Karla V. , Atherton, Pamela J. , Ajmera, Archana , Baghdadi, Tareq Al, Baumann, Brian C. , Beltran, Himisha , Berg, Stephanie , Chen, Ronald C. , Choudhury, Atish D. , Jacene, Heather A. , Kilari, Deepak , Kwok, Young , Swami, Umang , Tan, Alan , Yang, Yuanquan , Zhang, Tian , Galsky, Matthew D. , George, Daniel J. , Baghdadi, Tareq Al , Cole, Suzanne , Jacene, Heather A , Lang, Joshua M , Kilari, Deepak , Kwok, Young , McGregor, Bradley , Morris, Michael J , Parikh, Mamta , Swami, Umang , Tan, Alan , Yang, Yuanquan A , Zhang, Tian , Galsky, Matthew D , Rosenberg, Jonathan E , George, Daniel J , Choueiri, Toni K , Baumann, Brian C , Choudhury, Atish D , Chen, Ronald , Ballman, Karla , Berg, Stephanie A , Cole, Suzanne , Lang, Joshua M. , McGregor, Bradley A. , Morris, Michael J. , Choueiri, Toni K.

Mayo Clinic

Journal of Clinical Oncology | July 27, 2026 | Volume: 44 | Issue: 24 | Pages: 2341-2352

10.1200/jco-26-01135 | PMID 42507969 Get It

PURPOSE Bone metastases (BM) occur in approximately 30% of patients with metastatic renal cell carcinoma (mRCC) and are associated with poor survival and symptomatic skeletal events (SSEs). Radium-223, an alpha-emitting bone-seeking radioisotope, and cabozantinib, a tyrosine kinase inhibitor, have demonstrated activity in BM. RADICAL (Alliance A031801; ClinicalTrials.gov identifier: NCT04071223 ) evaluated cabozantinib ± radium-223 in mRCC with BM. METHODS This phase II trial enrolled patients with mRCC of any histology with ≥1 BM. Patients were randomly assigned 1:1 to cabozantinib ± radium-223, stratified by osteoclast-targeted therapy (OTT), prior therapy, opioid use, and International mRCC Database Consortium (IMDC) risk. The primary end point was SSE-free survival (SSE-FS). Secondary end points included safety, objective response rate (ORR), progression-free survival, and overall survival (OS). A target of 124 evaluable patients was planned, with a prespecified interim futility analysis at 50% of expected SSE-FS events; the trial would stop if the stratified hazard ratio (sHR) > 1.0. RESULTS The prespecified interim futility analysis was conducted after 90 patients were enrolled and crossed the futility boundary, leading to closure at 98 patients. The final analysis included all 98 patients. Median age was 63 years, 82.7% had clear cell histology, and 79.6% were using an OTT. IMDC risk was favorable (18.4%), intermediate (67.3%), and poor (14.3%). Median follow-up was 13.1 months. Median SSE-FS for cabozantinib with radium-223 versus cabozantinib was 16.7 versus 17.6 months (sHR, 1.46 [90% CI, 0.86 to 2.51]). Median OS was 28.3 versus 19.7 months (sHR, 1.40 [95% CI, 0.70 to 2.79]). ORR was 19.4% versus 25.0% ( P = .78). Grade ≥3 adverse events were similar across arms (69.6% v 75.5%). CONCLUSION Radium-223 did not improve SSE-FS when added to cabozantinib. The combination demonstrated a manageable safety profile.
Normothermic regional perfusion (NRP) use in controlled donation after circulatory determination of death (cDCDD): results of the European Society for Organ Transplantation Bucharest consensus conference
Cruz, José Luis Campo-Cañaveral de la , Croome, K, Feltrin, Giuseppe, Hessheimer, Amelia, Messer, Simon, Wall, Anji, Domínguez-Gil, Beatriz, Martin, Dominique, Oniscu, Gabriel, Cillo, Umberto, Miñambres, Eduardo , Berman, Marius , Antonini, Marta Velia , Croome, Kristopher P. , Feltrin, Giuseppe , Hessheimer, Amelia J. , Jorns, Carl , Domínguez‐Gil, Beatriz , Martin, Dominique , Oniscu, Gabriel C. , Cillo, Umberto

Mayo Clinic

Transplant International | July 22, 2026 | Volume: 39 | Issue: No issue available | Pages: No page available

10.3389/ti.2026.16391 | PMID 42558417 Get It

Normothermic Regional Perfusion (NRP) is emerging as a game-changer in enhancing outcomes for Donation after Circulatory Determination of Death (DCDD). NRP maintains physiological conditions through perfusion with oxygenated blood, outperforming conventional super-rapid recovery techniques significantly improving outcomes and organ utilization. Despite its clinical benefits, widespread adoption of NRP is impeded by heterogeneous organizational, legal, and ethical frameworks. At the ESOT Bucharest Consensus Conference, leading experts in transplantation achieved consensus on 130 relevant NRP-related open issues to facilitate its implementation and guide global practice. Key recommendations include criteria for adoption of NRP, minimal requirements, procedures to be adopted before and during NRP, donor organ evaluation criteria and sequence of organ harvesting. Consensus extends to procedural components (including the configuration of perfusion parameters and strategic team coordination), ethical integrity of NRP in the context of the dead donor rule and key unmet needs for future developments. While significant strides were made in unifying practice, unresolved issues regarding maximum warm ischemic time and variability in legal standards indicate avenues for future research. This consensus underscores the imperative for global standardization in NRP application, promising to elevate the success rates of organ transplants and establish NRP as a foundational element in the evolution of DCDD.
Dermatofibrosarcoma Protuberans of the Breast: Radiologic-Pathologic Correlation
Leming, Macy, Sharpe, Richard E. , Cui, Xiaoyan, Simmons, Curtis , Anderson, Sarah

Mayo Clinic

Journal of Breast Imaging | July 16, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/jbi/wbag054 | PMID 42993166 Get It

Abstract Dermatofibrosarcoma protuberans (DFSP) is a rare, locally aggressive, low-to-intermediate grade fibroblastic neoplasm arising from the skin that can uncommonly involve the breast and mimic primary breast malignancy. Dermatofibrosarcoma protuberans of the breast typically presents as a palpable, slow-growing superficial mass with an associated flesh-colored or red-brown skin lesion. On mammography, DFSP most often demonstrates an oval, circumscribed, equal or high-density mass. Ultrasound typically shows an oval hypoechoic or heterogeneous circumscribed mass, frequently with internal hypervascularity. MRI commonly demonstrates a superficial mass without circumscribed margins, with T1 hypointensity, T2 hyperintensity, and avid heterogeneous or homogeneous enhancement. Histologically, DFSP demonstrates uniform spindle cells in a storiform pattern with infiltrative extension into subcutaneous fat; immunochemistry is characteristically CD34-positive. Molecular testing can confirm the diagnosis by identifying a platelet-derived growth factor receptor Beta (PDGFB) fusion (classically collagen type I alpha 1 gene [COL1A1]: PDGFB) and may be helpful in limited sampling or atypical morphology. Treatment is complete surgical resection with negative margins, with re-excision for positive margins. Although local recurrence can occur, metastasis is uncommon, and long-term disease specific survival is excellent. Careful radiologic-pathologic correlation facilitates accurate diagnosis, concordance assessment after biopsy, and appropriate management.
Real-World Outcomes with BCMA- and GPRC5D-Targeting Bispecific Antibodies in Plasma Cell Leukemia
Gaballa, Mahmoud R. , Julian, Kelley , Afrough, Aimaz , Hansen, Doris K. , Goel, Utkarsh , Corraes, Andre De Menezes Silva, Dima, Danai , Rana, Masooma , Hosoya, Hitomi , Mikkilineni, Lekha , Fogel, Lindsay , Raza, Shahzad, Zanwar, Saurabh , Sannareddy, Aishwarya, Borogovac, Azra , Green, Kimberly M , Biran, Noa, Shune, Leyla, Ouchveridze, Evguenia, DeJarnette, Shaun, Ferreri, Christopher J, Richards, Tiffany, Bal, Susan , Ye, Jing Christine, Shain, Kenneth H. , Harada, Ken , Avila, Gabriel De, Voorhees, Peter, Khouri, Jack , Sidana, Surbhi , Lin, Yi, Patel, Krina K. , Sborov, Douglas W. , Gaballa, Mahmoud , De Menezes Silva Corraes, Andre , Banerjee, Rahul , Zanwar, Saurabh S , Borogovac, Azra , Davis, James A , Green, Kimberly , Zolotov, Eli , Herr, Megan M. , Abid, Muhammad Bilal , Bal, Susan , Ali, Hossam M , Kaur, Gurbakhash , Shain, Kenneth H , Castaneda Puglianini, Omar , Hassan, Hamza , Anderson, Larry D , Khouri, Jack , Sidana, Surbhi , Portuguese, Andrew J , Janakiram, Murali , Lee, Hans C , Patel, Krina , Sborov, Douglas W , Dima, Danai , Hosoya, Hitomi , Rana, Masooma S , Julian, Kelley L , Hansen, Doris K , Corraes, Andre De Menezes Silva , Raza, Shahzad , Banerjee, Rahul , Pasvolsky, Oren , Sannareddy, Aishwarya , Davis, James A. , Biran, Noa , Zolotov, Eli , Shune, Leyla , Atrash, Shebli , Ferreri, Christopher J. , Richards, Tiffany, Abid, Muhammad Bilal , Ali, Hossam M. , Ye, Jing Christine, Richard, Shambavi , Kaur, Gurbakhash , Puglianini, Omar Castañeda , Rossi, Adriana , Hassan, Hamza , Anderson, Larry D. , Voorhees, Peter M. , Portuguese, Andrew J. , Janakiram, Murali , Lee, Hans C. , Grajales‐Cruz, Ariel

Mayo Clinic

Blood Advances | July 2, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1182/bloodadvances.2026020826 | PMID 42392158 Get It

Patients with plasma cell leukemia (PCL) are generally excluded from pivotal T-cell redirecting bispecific antibody (BsAb) trials. We evaluated real-world outcomes in a multicenter retrospective study of 122 patients with primary or secondary PCL across 15 academic centers, categorized as 'active' (≥5% circulating plasma cells within 30 days of BsAb initiation) or 'historical'. In a heavily pretreated population, patients received teclistamab (37%), elranatamab (11%), talquetamab as a line of therapy (Tal LOT, 42%), or talquetamab as bridging therapy to CAR-T (Tal Bridge, 11%). Cytokine release syndrome (CRS) was grade 1-2 in 56% and grade 3-4 in 4%, whereas neurotoxicity was grade 1-2 in 16% and grade 3-4 in 5%. Among 110 evaluable patients, the overall response rate (ORR) was 55%, including 61% with Tal LOT, 58% with Tal Bridge, 46% with elranatamab, and 33% with teclistamab. With a median follow-up of 8.3 months, talquetamab demonstrated superior survival. Tal LOT showed a median progression-free survival (mPFS) of 5.5 months and a median overall survival (mOS) of 11.5 months, and both were unreached in the Tal Bridge cohort. In contrast, teclistamab and elranatamab showed a mPFS of 1.2 and 1.6 months and mOS of 8.1 and 3.6 months, respectively (P=0.007, P=0.023). In active PCL, Tal LOT achieved mPFS/mOS of 6.9/12.2 months versus 0.7/1.4 months with teclistamab and 1.0/3.1 months with elranatamab, respectively (P<0.001, P=0.002). Multivariable analysis associated active PCL with worse survival and Tal LOT with improved outcomes. BsAbs were safe in PCL, with talquetamab showing superior outcomes compared with BCMA-directed BsAbs.
Idecabtagene vicleucel and endogenous T‐cell phenotypes linked to progression‐free survival in relapsed multiple myeloma
Paiva, Bruno , Manrique, Irene , Thompson, Ethan, CAMPBELL, TIMOTHY B., Guerrero, Camila, Martin, Nathan, Anderson, Larry D. , Lonial, Sagar, Raje, Noopur S., Lin, Yi, Moreau, Philippe, San-Miguel, Jesus, Munshi, Nikhil C., Kaiser, Shari, Paiva, Bruno , Anderson, Larry D , Thompson, Ethan G., Berdeja, Jesús G. , Lonial, Sagar , Moreau, Philippe , San-Miguel, Jesus , Munshi, Nikhil C.

Mayo Clinic

HemaSphere | July 2, 2026 | Volume: 10 | Issue: 7 | Pages: No page available

10.1002/hem3.70423 | PMID 42396130 Get It

Abstract Improved understanding of how chimeric antigen receptor (CAR) and endogenous T‐cell phenotypes associate with progression‐free survival (PFS) is needed to individualize and improve immunotherapy outcomes in multiple myeloma (MM). We characterized and investigated the prognostic value of immune dynamics defined with multidimensional and computational flow cytometry in 258 bone marrow aspirates from 107 MM patients treated with idecabtagene vicleucel in the KarMMa trial. At screening, there was an association between longer PFS and increased percentages of PD1 + cytotoxic T cells and ICOS − TIGIT + Tregs. At Month 1 after infusion, the presence of >1% CAR‐T cells, a CD4/CD8 CAR‐T‐cell ratio >0.09, and greater abundance of non‐activated non‐cytolytic CAR‐T cells identified patients with longer PFS. Notably, 47 of the 115 endogenous T‐cell clusters were prognostic at the latest assessment performed after CAR‐T infusion. Lower percentages of ICOS + TIGIT − Tregs showed the strongest association with longer PFS. Altogether, this large dataset of dynamic immune profiling throughout treatment with anti‐B‐cell maturation antigen (anti‐BCMA) CAR‐T cells uncovered that the T‐cell composition prior to apheresis as well as CAR‐T and endogenous T‐cell phenotypes after infusion associates with PFS. These findings have potential for translation into routine laboratory practice for improved understanding of response and resistance to CAR‐T cells in relapsed/refractory MM.
Changes in Self-Reported Cognitive Complaints, Functional Impairments, Work Productivity, and Symptom Severity in Participants With Narcolepsy After Treatment With Greater Than 9 Gram Dosages of Low-Sodium Oxybate in the DUET Study (P3-14.003)
Schneider, Logan, Ruoff, Chad, Plante, David, Simmons, Jerald H., Nichols, Deborah A. , Steininger, Teresa, Whalen, M, Dai, Jing , Cairns, A., Ruoff, Chad , Ruoff, Chad M , Simmons, Jerald, Whalen, Marisa, Cairns, Alyssa , Bogan, Richard

Mayo Clinic

Neurology | June 10, 2026 | Volume: 106 | Issue: 11_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000215602 Get It